205 related articles for article (PubMed ID: 29081307)
81. Impact of Baseline Anxiety on Well-being in People with Post-COVID-19 Condition: A Secondary Analysis.
Kleine N; Kwan ATH; Le GH; Guo Z; Phan L; Subramaniapillai M; McIntyre RS
CNS Spectr; 2024 Apr; 29(2):150-154. PubMed ID: 38453677
[TBL] [Abstract][Full Text] [Related]
82. Effectiveness and Safety of Vortioxetine for Major Depressive Disorder in Real-World Clinical Practice: Results from the Single-Arm RELIEVE China Study.
Wang G; Xiao L; Ren H; Simonsen K; Ma J; Xu X; Guo P; Wang Z; Bai L; Heldbo Reines E; Hammer-Helmich L
Neuropsychiatr Dis Treat; 2022; 18():1939-1950. PubMed ID: 36065389
[TBL] [Abstract][Full Text] [Related]
83. A preliminary descriptive report of the longevity of the effects of Swedish Massage therapy for subjects with Generalized Anxiety Disorder.
Rapaport MH; Schettler PJ; Larson ER; Edwards SA; Dunlop BW; Rakofsky JJ; Kinkead B
J Bodyw Mov Ther; 2023 Jan; 33():176-181. PubMed ID: 36775516
[TBL] [Abstract][Full Text] [Related]
84. Treatment Effects of Vortioxetine on Cognitive Functions in Mild Alzheimer's Disease Patients with Depressive Symptoms: A 12 Month, Open-Label, Observational Study.
Cumbo E; Cumbo S; Torregrossa S; Migliore D
J Prev Alzheimers Dis; 2019; 6(3):192-197. PubMed ID: 31062834
[TBL] [Abstract][Full Text] [Related]
85. A multicomponent yoga-based, breath intervention program as an adjunctive treatment in patients suffering from generalized anxiety disorder with or without comorbidities.
Katzman MA; Vermani M; Gerbarg PL; Brown RP; Iorio C; Davis M; Cameron C; Tsirgielis D
Int J Yoga; 2012 Jan; 5(1):57-65. PubMed ID: 22346068
[TBL] [Abstract][Full Text] [Related]
86. Long-Term Chamomile Therapy of Generalized Anxiety Disorder: A Study Protocol for a Randomized, Double-Blind, Placebo- Controlled Trial.
Mao JJ; Li QS; Soeller I; Rockwell K; Xie SX; Amsterdam JD
J Clin Trials; 2014 Nov; 4(5):. PubMed ID: 29057164
[TBL] [Abstract][Full Text] [Related]
87. Vortioxetine Improves Depressive Symptoms and Cognition in Parkinson's Disease Patients with Major Depression: An Open-Label Prospective Study.
Santos García D; Alonso Losada MG; Cimas Hernando I; Cabo López I; Yáñez Baña R; Alonso Redondo R; Paz González JM; Cores Bartolomé C; Feal Painceiras MJ; Íñiguez Alvarado MC; Labandeira C; García Díaz I
Brain Sci; 2022 Oct; 12(11):. PubMed ID: 36358393
[TBL] [Abstract][Full Text] [Related]
88. Agomelatine for the Treatment of Generalized Anxiety Disorder: A Meta-Analysis.
Wang SM; Woo YS; Kim NY; Na HR; Lim HK; Bahk WM
Clin Psychopharmacol Neurosci; 2020 Aug; 18(3):423-433. PubMed ID: 32702221
[TBL] [Abstract][Full Text] [Related]
89. Vortioxetine - pharmacological properties and use in mood disorders. The current state of knowledge.
Krupa AJ; Wojtasik-Bakalarz K; Siwek M
Psychiatr Pol; 2023 Dec; 57(6):1109-1126. PubMed ID: 36571300
[TBL] [Abstract][Full Text] [Related]
90. Effect of Osteopathic Manipulative Therapy on Generalized Anxiety Disorder.
Dixon L; Fotinos K; Sherifi E; Lokuge S; Fine A; Furtado M; Anand L; Liberatore K; Katzman MA
J Am Osteopath Assoc; 2020 Mar; 120(3):133-143. PubMed ID: 32091557
[TBL] [Abstract][Full Text] [Related]
91. An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder.
Shah A; Northcutt J
Ann Gen Psychiatry; 2018; 17():19. PubMed ID: 29760763
[TBL] [Abstract][Full Text] [Related]
92. Quality of Life and Medication Adherence in Patients With Major Depressive Disorder: An Interim Analysis of a Randomized Study.
Santi NS; Biswal SB; Naik BN; Sahoo JP; Rath B
Cureus; 2023 Jun; 15(6):e39997. PubMed ID: 37415997
[TBL] [Abstract][Full Text] [Related]
93. [Use of medicinal plants in patients with symptoms of generalized anxiety].
Romero-Cerecero O; Islas-Garduño AL; Tortoriello-García J
Rev Med Inst Mex Seguro Soc; 2019 Dec; 57(6):364-370. PubMed ID: 33001612
[TBL] [Abstract][Full Text] [Related]
94. Vortioxetine versus sertraline in metabolic control, distress and depression in Mexican patients with type 2 diabetes.
Tovilla-Zárate CA; Pérez-Mandujano A; Ramírez-González IR; Fresan A; Suarez-Mendez S; Martínez-Villaseñor E; Rodríguez-Sánchez E; Villar-Soto M; López-Narváez ML; González-Castro TB; Ble-Castillo JL; Juárez-Rojop IE
Ann Transl Med; 2019 Nov; 7(22):656. PubMed ID: 31930057
[TBL] [Abstract][Full Text] [Related]
95. Disability and health-related quality of life in outpatients with generalised anxiety disorder treated in psychiatric clinics: is there still room for improvement?
Bobes J; Caballero L; Vilardaga I; Rejas J
Ann Gen Psychiatry; 2011 Mar; 10(1):7. PubMed ID: 21401940
[TBL] [Abstract][Full Text] [Related]
96. Plasma Neuropeptide-S Levels in Populations Diagnosed with Generalized Anxiety Disorder: A Controlled Study.
Baykan H; Baykan Ö; Durmaz O; Kara H; Hişmioğullari AA; Karlidere T
Noro Psikiyatr Ars; 2019 Mar; 56(1):52-56. PubMed ID: 30911238
[TBL] [Abstract][Full Text] [Related]
97. Effects of Vortioxetine Versus Placebo on Cognition and Functional Capacity in Adults With Posttraumatic Stress Disorder.
Durand D; Calcagno TM; Wong A; Newport DJ; Nemeroff CB; Dunlop BW; Harvey PD
J Clin Psychopharmacol; 2021 Jul-Aug 01; 41(4):501-503. PubMed ID: 34145182
[No Abstract] [Full Text] [Related]
98. A Brazilian Case of Treatment-Resistant Generalized Anxiety Disorder Successfully Treated with Monoamine Oxidase Inhibitor (MAOI).
Faria CGF; Fidry M; do Cabo MC; Quagliato LA; Nardi AE; Zaman R; Freire R
Psychiatr Danub; 2020 Sep; 32(Suppl 1):139-141. PubMed ID: 32890377
[TBL] [Abstract][Full Text] [Related]
99. Poor man's vortioxetine.
Feinberg SS
CNS Spectr; 2022 Oct; 27(5):541-542. PubMed ID: 33504387
[No Abstract] [Full Text] [Related]
100. Effects of Vortioxetine Versus Placebo on Cognition and Functional Capacity in Adults With Posttraumatic Stress Disorder: Erratum.
J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):616. PubMed ID: 34519458
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
